Fulcrum Therapeutics
FULC· Manufacturing· Fiscal year ends in December
CEO pay in FY2025Stock +140.6% in FY2025
Alex C. Sapir is the CEO of Fulcrum Therapeutics and was paid $3.3M in FY2025 (Dec), up 224%.
Pay$100 in the stock at the end of FY22 → $155
Executives3
See all- 1Alex C. SapirPresident and Chief Executive OfficerFY2025
- 2Alan MussoChief Financial OfficerFY2025
- 3Curtis OltmansChief Legal Officer and Head of External AffairsFY2025
Named executives and their total pay, from the Summary Compensation Table of the latest proxy.
Pay
See allFulcrum Therapeutics paid its 3 named executives $6.5M in total in FY2025 (Dec). CEO Alex C. Sapir was paid $3.3M of that.
| Name | |||
|---|---|---|---|
| Alex C. SapirPresident and Chief Executive Officer | |||
| Alan MussoChief Financial Officer | |||
| Curtis OltmansChief Legal Officer and Head of External Affairs |
of each named executive, from the Summary Compensation Table of each proxy.
Peers
No disclosed peer group
No proxy on file names a pay peer group for Fulcrum Therapeutics. The peer group comes from the proxy statement, so it shows here when a proxy read has it.
Board2
See all- Alan EzekowitzDirector · 8 yr on the boardIndependentCompensation and Human Capital Management (Chair), Science and Technology—Paid as an executive
- Rachel KingDirector · 0 yr on the boardIndependentCompensation and Human Capital Management—Paid as an executive
The board of the latest proxy (FY2024).
Activity
Filings6
See all| Proxy statement | DEF 14A | Apr 30, 2026 | FY2025 |
| Annual report | 10-K | Feb 24, 2026 | FY2025 |
| Proxy statement | DEF 14A | Apr 30, 2025 | FY2024 |
| Annual report | 10-K | Feb 25, 2025 | FY2024 |
| Proxy statement | DEF 14A | Apr 19, 2024 | FY2023 |
| Annual report | 10-K | Feb 27, 2024 | FY2023 |
